About Dr. Wierda
CLL is a unique disease in which to do translational research because of the circulating tumor cells that can be sampled before, during and after treatment; providing the exceptional opportunity to study and confirm in vivo mechanisms of drug action and for hypothesis testing. MD Anderson Cancer Center (MDACC) is a uniquely established clinical Institution in which to perform translational research. Over three-fourths of patients with CLL are enrolled on clinical trial and provide tissue samples before, during, and after treatment for correlative studies. Most of the drugs currently approved for CLL have been developed and/or investigated at MDACC, including fludarabine, alemtuzumab, ofatumumab, and rituximab.
Dr. Wierda is uniquely qualified to be the Principal Investigator (PI) for this grant owing clinical and translational research and expertise in CLL. In 2001, Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC. He was promoted to Associate Professor of Medicine in 2007. In 2012, he was promoted to Professor of Medicine and continue clinical and translational research in CLL. Dr. Wierda’s outpatient clinical activities are more than 90% dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been PI, Co-PI, or collaborator on numerous clinical trials and conduct translational research in CLL. He has published many peer-reviewed articles on various clinical and translational aspects of CLL and drug development and have given numerous lectures on treatments for patients with CLL. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
D.B. Lane Cancer Research Distinguished Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief - Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Center Medical Director, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Executive Medical Director, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Wierda's research is in Chronic Lymphocytic Leukemia (CLL) prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, and developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Dr. Wierda's clinical interest is providing Chronic Lymphocytic Leukemia (CLL) patients with the best treatment options including immune and gene therapies, chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients.
|1993||University of Health Sciences/The Chicago Medical School, North Chicago, IL, USA, MD|
|1992||University of Health Sciences/The Chicago Medical School, North Chicago, IL, USA, PHD, Microbiology and Immunology|
|1986||University of California, Riverside, CA, USA, BS, Biochemistry|
Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2012
Co-Chairman, MDACC CLL Moon Shot, Houston, TX, 2014 - Present
Institutional Committee Activities
Member, Promotions and Tenure Committee (PTC, 2018 - 2021
Member, Virtual Care Committee, 2018 - Present
Member, Clinical Research Advisory Committee, 2014 - Present
Co-Chair, Inpatient Operations Steering Committee, 2014 - Present
Member, EMR Strategy Review Committee Strategic Vision and Goals Workgroup, 2011 - Present
Member, 24 Hour Medical Coverage Steering Committee, 2010 - Present
Member, ICU Subcommittee, 2010 - Present
Member, Institutional Chemotherapy Biotherapy Policy Task Force, 2010 - Present
|2018||2018 Faculty Achievement Award in Patient Care, MD Anderson Cancer Center|
|2017||Melvin L. Samuels Award for Excellence in Patient Care, MD Anderson Division of Cancer Medicine|
|2017||D.B. Lane Cancer Research Distinguished Professor|
|2011||Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine - UT MD Anderson Cancer Center|
- Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
- Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabham S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell C, Osterborg A.. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clin Lymphoma Myeloma 9(6):E36, 2009. PMID: 19951868.
- Motta M, Wierda WG, Ferrajoli A. Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-41, 2009. e-Pub 2009. PMID: 19536902.
- Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 2009. e-Pub 2009. PMID: 19224852.
- Wierda W. New prognostic factors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(1):32-42, 2009. PMID: 19274038.
- Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. PMID: 17917961.
- Wierda W, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M.. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. e-Pub 2007. PMID: 17299097.
- Wierda WG, Kipps J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3):557-68, 2007.
- Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 2006. PMID: 16353201.
- Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 2005. PMID: 16201050.
- Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 2005. e-Pub 2005. PMID: 15767647.
- Wierda WG, Keating MJ, O’Brien S. Refractory chronic lymphocytic leukemia – prognosis and treatment options. Am J Cancer 3(3):163-178, 2004.
- Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Strange M, Nielsen TG, Russell CA.. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 114(22):90, 2009.
- Wierda WG, Keating MJ, O'Brien S.. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 8th. Lipppincott Williams & Wilkins: Philadelphia, 2278-2292, 2009.
- Cortes JE, , Kantarjian H.bWierda W||. Chronic Leukemias. In: Conn's Current Therapy. W. B. Saunders Company Publications: Pennsylvania, 456-463, 2009.
- Wierda, WG. Gene Therapy, Vaccines and Immune Modulation. In: Chronic Lymphocytic Leukemia. Informa Healthcare, 2008.
- Wierda WG. Gene Therapeutic Approaches for Chronic Lymphocytic Leukemia. In: Unknown, 201-215, 2008.
|Title:||Phase 1 study of 8-Cl-adenosine in CLL. Protocol 2004-0144|
|Funding Source:||Food and Drug Administration (FDA)|
|Title:||LAB03-0893 Cellular Therapy for CLL Utilizing Chimeric Antigen Receptors (CARs)|
|Funding Source:||CLL Global Research Foundation|
|Title:||Chronic Lymphocytic Leukemia Research Consortium Core D|
|Title:||Chronic Lymphocytic Leukemia Research Consortium Core D multi|
|Title:||2011-0612 An Extention Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects with Hematologic Malignancies|
|Funding Source:||Gilead Sciences, Inc|